Self-administration of a novel subcutaneous bradykinin b(2) receptor antagonist, icatibant, as an effective treatment option in patients with hereditary angioedema

Ítems similars

• Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema
  per: Cicardi, M., et al.
  Publicat: (2010)
• Safety and efficacy of icatibant self-administration for acute hereditary angioedema
  per: Boccon-Gibod, I, et al.
  Publicat: (2012)
• 164 Treatment of Acquired Angioedema with the Bradykinin Receptor Antagonist Icatibant
  per: Siani, Maria Concetta, et al.
  Publicat: (2012)
• Early presentation of clinical hereditary angioedema symptoms in an infant
  per: Pham, Hoang, et al.
  Publicat: (2014)
• Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain
  per: Blasco, Antonio J, et al.
  Publicat: (2013)